Anne Wojcicki
-
23andMe launches new diabetes risk test, but experts are wary of its benefit
In contrast to 23andMe’s previous FDA approvals for genetic risk tests for conditions like Alzheimer’s, the diabetes assessment did not go through the FDA clearance pathway because it was characterized as a wellness product not intended to make diagnoses and provide medical advice.
-
Highlight of #JPM16: Crowd shushes 23andMe CEO Anne Wojcicki
23andMe CEO Anne Wojcicki got a little chatty during her own company’s presentation. Oops.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
23andMe CEO happy to be back in business, looking toward the future
23andMe can finally take a deep breath and move forward following FDA approval, and CEO Anne Wojcicki is doing just that.
-
Health IT, Hospitals, Startups
Anne W. and 23andMe: Still cool but still stalled
Anne Wojcicki made a strong case for getting your DNA sequenced to the crowd at SxSW but she had no easy answers for questions about privacy or the FDA.